Jordan J Feld1, Raoel Maan1,2, Stefan Zeuzem3, Alexander Kuo4, David R Nelson5, Adrian M Di Bisceglie6, Michael P Manns7, Ken Sherman8, Lynn M Frazier9, Richard Sterling10, Mark Mailliard11, Monica Schmidt12, Lucy Akushevich13, Monika Vainorius13, Michael W Fried13. 1. Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto, Ontario, Canada. 2. Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. 3. Goethe University Hospital, Frankfurt, Germany. 4. University of California, San Diego. 5. University of Florida, Gainesville. 6. Saint Louis University School of Medicine, Missouri. 7. Hannover Medical School, Germany. 8. University of Cincinnati, Ohio. 9. Liver Wellness Center, Little Rock, Arkansas. 10. Virginia Commonwealth University Health System, Richmond. 11. University of Nebraska Medical Center, Omaha. 12. University of North Carolina, Chapel Hill. 13. Carolinas Healthcare System, Charlotte, North Carolina.
Abstract
BACKGROUND: Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in patients with cirrhosis. This study reports the effectiveness and safety of SOF-based therapy in patients with GT3 HCV treated in clinical practice. METHODS: Hepatitis C Virus Therapeutic Registry and Research Network is an international, prospective observational study evaluating patients treated in usual clinical practice. Patients with GT3 HCV were analyzed to assess predictors of treatment response and adverse events using descriptive statistics and multivariable logistic regression. RESULTS: Treatment outcomes were available for 197 patients treated with SOF and ribavirin (RBV), with or without peginterferon, including 54% with cirrhosis and 49% who failed prior therapy. Of 178 patients treated with SOF/RBV, 60% achieved SVR at 12 weeks (SVR12), compared with 84% of 19 patients treated with SOF/peginterferon/RBV. For patients treated with SOF/RBV, the SVR12 rate was 58% in treatment-naive patients with cirrhosis, and 42% in those with cirrhosis who failed prior therapy. In noncirrhotic patients, SVR12 rates were 89% in treatment-naive and 88% in treatment-experienced patients. After controlling for age and sex, absence of cirrhosis (odds ratio [OR], 6.4; 95% confidence interval [CI], 2.78-14.74), albumin levels ≥3.2 g/dL (OR, 12.48; 95% CI, 3.86-40.33), and platelet count >10(5) cells/µL (OR, 7.44; 95% CI, 3.51-15.78) were associated with greater odds of SVR12 CONCLUSIONS: SVR rates were acceptable in patients with GT3 HCV without cirrhosis; however, in those with cirrhosis, treatment with SOF/RBV was suboptimal, highlighting the need for new therapies for this population.
BACKGROUND:Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in patients with cirrhosis. This study reports the effectiveness and safety of SOF-based therapy in patients with GT3 HCV treated in clinical practice. METHODS:Hepatitis C Virus Therapeutic Registry and Research Network is an international, prospective observational study evaluating patients treated in usual clinical practice. Patients with GT3 HCV were analyzed to assess predictors of treatment response and adverse events using descriptive statistics and multivariable logistic regression. RESULTS: Treatment outcomes were available for 197 patients treated with SOF and ribavirin (RBV), with or without peginterferon, including 54% with cirrhosis and 49% who failed prior therapy. Of 178 patients treated with SOF/RBV, 60% achieved SVR at 12 weeks (SVR12), compared with 84% of 19 patients treated with SOF/peginterferon/RBV. For patients treated with SOF/RBV, the SVR12 rate was 58% in treatment-naive patients with cirrhosis, and 42% in those with cirrhosis who failed prior therapy. In noncirrhotic patients, SVR12 rates were 89% in treatment-naive and 88% in treatment-experienced patients. After controlling for age and sex, absence of cirrhosis (odds ratio [OR], 6.4; 95% confidence interval [CI], 2.78-14.74), albumin levels ≥3.2 g/dL (OR, 12.48; 95% CI, 3.86-40.33), and platelet count >10(5) cells/µL (OR, 7.44; 95% CI, 3.51-15.78) were associated with greater odds of SVR12 CONCLUSIONS: SVR rates were acceptable in patients with GT3 HCV without cirrhosis; however, in those with cirrhosis, treatment with SOF/RBV was suboptimal, highlighting the need for new therapies for this population.
Authors: Fasiha Kanwal; Tuyen Hoang; Jennifer R Kramer; Steven M Asch; Matthew Bidwell Goetz; Angelique Zeringue; Peter Richardson; Hashem B El-Serag Journal: Gastroenterology Date: 2010-12-22 Impact factor: 22.682
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Stuart C Gordon; Andrew J Muir; Joseph K Lim; Brian Pearlman; Curtis K Argo; Ananthakrishnan Ramani; Benedict Maliakkal; Imtiaz Alam; Thomas G Stewart; Monika Vainorius; Joy Peter; David R Nelson; Michael W Fried; K Rajender Reddy Journal: J Hepatol Date: 2014-09-10 Impact factor: 25.083
Authors: Zobair M Younossi; Maria Stepanova; Michael Estep; Francesco Negro; Paul J Clark; Sharon Hunt; Qinghua Song; Matthew Paulson; Luisa M Stamm; Diana M Brainard; G Mani Subramanian; John G McHutchison; Keyur Patel Journal: J Hepatol Date: 2015-09-01 Impact factor: 25.083
Authors: S S Solomon; M S Sulkowski; P Amrose; A K Srikrishnan; A M McFall; B Ramasamy; M S Kumar; S Anand; D L Thomas; S H Mehta Journal: J Viral Hepat Date: 2017-08-14 Impact factor: 3.728
Authors: Adriano Pellicelli; Vincenzo Messina; Valerio Giannelli; Marco Distefano; Valeria Pace Palitti; Pascal Vignally; Pierluigi Tarquini; Antonio Izzi; Alessandra Moretti; Sergio Babudieri; Serena Dell'Isola; Massimo Marignani; Gaetano Scifo; Vincenzo Iovinella; Giuseppe Cariti; Maurizio Pompili; Francesco Di Candilo; Luca Fontanella; Giuseppe M Ettorre; Giovanni Vennarecci; Antonio Massimo Ippolito; Giorgio Barbarini Journal: Gut Liver Date: 2020-05-15 Impact factor: 4.519
Authors: Paul Kwo; Michael W Fried; K Rajender Reddy; Consuelo Soldevila-Pico; Saro Khemichian; Jama Darling; Phillippe J Zamor; Andrew A Napoli; Beatrice Anduze-Faris; Robert S Brown Journal: Hepatol Commun Date: 2018-02-27